ATC Group: C09DB Angiotensin II antagonists and calcium channel blockers

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C09DB in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C09 Agents acting on the renin-angiotensin system
3 C09D Angiotensin II antagonists, combinations
4 C09DB Angiotensin II antagonists and calcium channel blockers

Group C09DB contents

Code Title
C09DB01 Valsartan and amlodipine
C09DB02 Olmesartan medoxomil and amlodipine
C09DB04 Telmisartan and amlodipine
C09DB05 Irbesartan and amlodipine
C09DB06 Losartan and amlodipine
C09DB07
C09DB09

Active ingredients in C09DB

Active Ingredient

Combination of two antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: an angiotensin II receptor antagonist, candesartan and a dihydropyridinic calcium channel blocker, amlodipine. The combination of these substances has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone.

The pharmacodynamic properties of each drug, irbesartan and amlodipine, provide an additive antihypertensive effect when administered in combination compared to the effect of each drug administered separately. Irbesartan is a specific angiotensin II receptor antagonist (AT1 subtype) and amlodipine is a dihydropyridine calcium antagonist. Both AT1 receptor antagonists and calcium channel blockers lower blood pressure by reducing peripheral resistance, but calcium influx blockade and reduction of angiotensin II vasoconstriction are complementary mechanisms.

Combination of an angiotensin II receptor antagonist, olmesartan medoxomil, and a calcium channel blocker, amlodipine besilate. The combination of these active ingredients has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone.

Combination of two antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: an angiotensin II receptor antagonist, telmisartan, and a dihydropyridinic calcium channel blocker, amlodipine. The combination of these substances has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone.

Combination of two antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: amlodipine belongs to the calcium antagonist class and valsartan to the angiotensin II antagonist class of medicines. The combination of these substances has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone.

Related product monographs

Document Type Information Source  
 APROVASC Film-coated tablet MPI, Generic Marketing Authorisation Holder
 CLODIPAN Hard capsule MPI, EU: SmPC Medicines Authority (MT)
 COPALIA Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)
 EXFORGE Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)
 SEVIKAR Film-coated tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 TWYNSTA Tablet MPI, EU: SmPC European Medicines Agency (EU)